Literature DB >> 26170788

Stevens-Johnson Syndrome triggered by a combination of clobazam, lamotrigine and valproic acid in a 7-year-old child.

A K Yapici1, M K Fidanci2, S Kilic3, N Balamtekin4, M Mutluay Arslan5, S T Yavuz6, S Kalman7.   

Abstract

Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) are diseases within the spectrum of severe cutaneous adverse reactions affecting skin and mucous membranes. Antiepileptic drugs (AEDs) are used in combination, leading to potential pharmacokinetic or pharmacodynamic interactions, causing more adverse effects than might occur when the AED is taken as monotherapy. Here, we report a rare case of SJS triggered by a combination of clobazam, lamotrigine and valproic acid in a 7-year-old boy. Because of inadequate seizure control, lorazepam was replaced with clobazam. Four weeks after the addition of clobazam, the patient developed SJS with a generalized rash, fever, with liver and kidney involvement, and eosinophilia one week after the initiation of treatment. All antiepileptic drugs were discontinued, and intravenous methylprednisolone, prophylactic systemic antibiotics, intravenous fluid supplement, antipyretic, special wound care, and supportive medical care for SJS were administered. He was discharged in a stable condition on the 18th day. Our case suggests that a drug-drug interaction between valproate, lamotrigine and clobazam contributed to the development of SJS. When the clobazam was added to valproic acid and lamotrigine co-medication, the lamotrigine dose should have been decreased.

Entities:  

Keywords:  Stevens-Johnson Syndrome; clobazam; lamotrigine; toxic epidermal necrolysis; valproic acid

Year:  2014        PMID: 26170788      PMCID: PMC4441308     

Source DB:  PubMed          Journal:  Ann Burns Fire Disasters        ISSN: 1592-9558


  17 in total

Review 1.  Adverse effects of antiepileptic drugs: a brief overview of important issues.

Authors:  Joyce A Cramer; Scott Mintzer; James Wheless; Richard H Mattson
Journal:  Expert Rev Neurother       Date:  2010-06       Impact factor: 4.618

2.  Effect of antiepileptic drug comedication on lamotrigine clearance.

Authors:  David Weintraub; Richard Buchsbaum; Stanley R Resor; Lawrence J Hirsch
Journal:  Arch Neurol       Date:  2005-09

3.  Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study.

Authors:  Jürgen Schneck; Jean-Paul Fagot; Peggy Sekula; Bruno Sassolas; Jean Claude Roujeau; Maja Mockenhaupt
Journal:  J Am Acad Dermatol       Date:  2007-10-04       Impact factor: 11.527

Review 4.  Toxic epidermal necrolysis in children: medical, surgical, and ophthalmologic considerations.

Authors:  Sunali Goyal; Punkaj Gupta; Colleen M Ryan; Melanie Kazlas; Natan Noviski; Robert L Sheridan
Journal:  J Burn Care Res       Date:  2009 May-Jun       Impact factor: 1.845

5.  Photo-induced toxic epidermal necrolysis caused by clobazam.

Authors:  P Redondo; J Vicente; A España; M L Subira; I De Felipe; E Quintanilla
Journal:  Br J Dermatol       Date:  1996-12       Impact factor: 9.302

Review 6.  Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding.

Authors:  Lars E French
Journal:  Allergol Int       Date:  2006-03       Impact factor: 5.836

Review 7.  Toxic epidermal necrolysis (Lyell's disease).

Authors:  Mario Lissia; Pietro Mulas; Antonio Bulla; Corrado Rubino
Journal:  Burns       Date:  2009-09-18       Impact factor: 2.744

8.  Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme.

Authors:  S Bastuji-Garin; B Rzany; R S Stern; N H Shear; L Naldi; J C Roujeau
Journal:  Arch Dermatol       Date:  1993-01

9.  Comparison and predictors of rash associated with 15 antiepileptic drugs.

Authors:  H Arif; R Buchsbaum; D Weintraub; S Koyfman; C Salas-Humara; C W Bazil; S R Resor; L J Hirsch
Journal:  Neurology       Date:  2007-05-15       Impact factor: 9.910

Review 10.  Toxic epidermal necrolysis and Stevens-Johnson syndrome.

Authors:  Thomas Harr; Lars E French
Journal:  Orphanet J Rare Dis       Date:  2010-12-16       Impact factor: 4.123

View more
  6 in total

1.  PharmGKB summary: clobazam pathway, pharmacokinetics.

Authors:  Rachel Huddart; J Steven Leeder; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2018-04       Impact factor: 2.089

Review 2.  Treatment Strategies for Dravet Syndrome.

Authors:  Kelly G Knupp; Elaine C Wirrell
Journal:  CNS Drugs       Date:  2018-04       Impact factor: 5.749

3.  Carbamazepine-induced Life-threatening Stevens-Johnson Syndrome and Agranulocytosis: The Maiden Case.

Authors:  A Avinash; V Mohanbabu Amberkar; Sushil Kiran Kunder; Sharath Madhyastha; K Meenakumari
Journal:  J Clin Diagn Res       Date:  2016-12-01

Review 4.  Recent Advances in the Drug Treatment of Dravet Syndrome.

Authors:  Elaine C Wirrell; Rima Nabbout
Journal:  CNS Drugs       Date:  2019-09       Impact factor: 5.749

Review 5.  Cutaneous Adverse Effects of Neurologic Medications.

Authors:  Eman Bahrani; Chloe E Nunneley; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 6.497

6.  Drug-induced hypersensitivity syndrome caused by valproic acid as a monotherapy for epilepsy: First case report in Asian population.

Authors:  X T Wu; P W Hong; D J Suolang; D Zhou; H Stefan
Journal:  Epilepsy Behav Case Rep       Date:  2017-06-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.